REGENXBIO (NASDAQ:RGNX) Insider Sells $53,033.40 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 5,124 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $10.35, for a total value of $53,033.40. Following the transaction, the insider directly owned 247,926 shares in the company, valued at $2,566,034.10. This represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

REGENXBIO Stock Performance

RGNX stock opened at $8.57 on Friday. The stock has a fifty day moving average of $11.00 and a 200-day moving average of $11.45. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $16.19. The company has a market capitalization of $442.30 million, a price-to-earnings ratio of -2.28 and a beta of 1.08.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.29). The business had revenue of $30.34 million for the quarter, compared to analysts’ expectations of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. Equities analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

Hedge Funds Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its stake in REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after acquiring an additional 594,161 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of REGENXBIO by 64.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock valued at $16,709,000 after acquiring an additional 454,977 shares in the last quarter. Invenomic Capital Management LP bought a new stake in shares of REGENXBIO during the 3rd quarter valued at about $4,120,000. Integral Health Asset Management LLC boosted its position in shares of REGENXBIO by 57.1% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $10,615,000 after acquiring an additional 400,000 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of REGENXBIO by 15.2% during the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock worth $32,929,000 after purchasing an additional 301,858 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Phase 1/2 AFFINITY interim data for RGX‑202 showed early efficacy signals and the company reported no evidence of liver injury in the study — a material safety datapoint that supports the program’s clinical outlook. Positive interim data for Regenxbio’s gene therapy in DMD
• Neutral Sentiment: Insider activity: director/officer Steve Pakola sold 5,124 shares at about $10.35 (disclosed 3/12–3/13). The sale is small (~2% reduction of his holding) but attracts attention in a thinly traded, volatile name. REGENXBIO Insider Sells
• Negative Sentiment: Multiple law firms have filed or are soliciting class‑action claims against REGENXBIO covering a multi‑year period (lead‑plaintiff deadlines around April 14, 2026). The wave of filings raises settlement/legal risk and creates sustained headline pressure. Schall Law Firm class action notice
• Negative Sentiment: Analyst/headline pressure: HC Wainwright published a bearish Q1 earnings forecast, adding sell‑side pressure after REGENXBIO’s recent March 5 quarter where EPS and revenue missed consensus — a reminder of near‑term execution and cash‑flow risks that can weigh on valuation. HC Wainwright bearish forecast

Analyst Upgrades and Downgrades

RGNX has been the topic of a number of recent research reports. Stifel Nicolaus increased their price objective on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Chardan Capital decreased their price target on REGENXBIO from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Barclays initiated coverage on shares of REGENXBIO in a report on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price target on the stock. Finally, UBS Group restated an “overweight” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Tuesday, February 10th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.